FDA Implications of 3D Printing? | Deloitte US has been added to your bookmarks.
How can medical device makers assess the FDA implications of 3D printing?
Adhering to FDA regulations on the manufacture of medical devices might be simpler when it’s more complicated.
March 22, 2017 | Health care
That is to say: When manufacturers work in the traditional model of large-scale, industrial production, they know the rules and are prepared to work under them. But what about when the manufacturing process becomes simpler—as in the case of 3D printing? How do the rules apply to that new frontier?
3D printing, or additive manufacturing (AM), offers device makers a range of potential advantages. They can be more innovative in design, address needs in a more customized way, and deliver products directly at the point of use. AM opens the door to offerings that would previously have been cost-inefficient because of scale.
But from a regulatory standpoint, AM is
One way some health organizations have addressed that challenge has been to sidestep it—by sticking to the uses of AM that are not regulated, such as collaborative “
But to realize AM’s full potential to change care, its users must venture into the realm of regulated device classes. These devices, which “touch the patient,” may follow different paths to market, but they all have to meet the FDA’s pre-market and post-market requirements.
What does that mean for AM? It depends on how a company uses it. Some AM strategies create
A company on a static path may use AM only for operations like rapid prototyping, and its regulatory concerns might be limited to design controls, process validation, and production and process controls. A company that uses AM to evolve its business model, perhaps through mass customization at the point of use, might also have to address rules on pre-market approval and notification, quality system regulations (QSRs), or labeling.
With AM rapidly adding capabilities—and with more and more competitors actively exploring its potential—regulation should not be a reason to shy away from its use. As with any regulatory challenge, the path forward involves discrete, thoughtful steps. Start by defining the strategic aim that AM is meant to advance. Does carrying out that strategy
This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor.
Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.